Thus, in this research, we focused on metabolites that can differentiate AML status based on specific conditions, namely, treatment outcome (CR and NR), treatment regimen in patients with CR, risk classification, and presence or absence of FLT3-ITD mutation. Here, FLT3 is linked to acute myeloid leukemia.